CA
CAIHF.US Chia Tai Enterprises International Limited
- Market cap
- USD 257M
- P/E
- 10.7x
- P/B
- 0.88x
- ROE
- 6.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CAIHF.US undervalued?
Graham numberCAIHF.US trades 35.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chia Tai Enterprises International Limited fundamental analysis
No fundamental analysis for Chia Tai Enterprises International Limited yet.
Chia Tai Enterprises International Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chia Tai Enterprises International Limited
CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance …
Full company profileChia Tai Enterprises International Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chia Tai Enterprises International Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 87.3M | 74.5M | 93.4M | 106M | 93.6M | 142M | 160M | 174M | 309M | 537M | 422M |
| Gross Profit | 31.2M | 22.0M | 27.3M | 29.1M | 24.9M | 34.6M | 39.3M | 30.2M | 49.1M | 77.6M | 69.3M |
| Operating Income | 6.92M | 613K | 2.99M | 3.71M | 1.29M | 4.95M | 4.89M | -4.54M | 11.2M | 38.9M | 24.8M |
| EBITDA | 12.3M | 5.73M | 7.81M | 8.35M | 5.97M | 12.5M | 11.8M | 11.3M | 23.6M | 48.4M | 24.8M |
| Net Income | 8.06M | 16.3M | 21.2M | 15.9M | 16.3M | 19.5M | -6.69M | 2.55M | 11.2M | 32.1M | 18.8M |
| EPS | 0.03 | 0.06 | 0.08 | 0.06 | 0.06 | 0.08 | -0.03 | 0.01 | 0.04 | 0.13 | 0.08 |
| Balance Sheet | |||||||||||
| Total Assets | 200M | 230M | 268M | 293M | 331M | 365M | 350M | 377M | 422M | 462M | 505M |
| Total Liabilities | 20.4M | 32.7M | 58.2M | 70.2M | 80.1M | 81.7M | 94.7M | 125M | 162M | 154M | 179M |
| Shareholders' Equity | 149M | 174M | 186M | 199M | 228M | 253M | 231M | 228M | 235M | 277M | 294M |
| Cash & Short-term Investments | 37.1M | 33.7M | 53.4M | 37.8M | 32.3M | 31.1M | 30.8M | 37.6M | 32.4M | 39.8M | 37.2M |
| Total Debt | - | - | - | 16.0M | 20.5M | 42.6M | 49.1M | 78.2M | 69.1M | 47.9M | 75.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.3M | -1.59M | 16.6M | -5.46M | 4.03M | -323K | 5.63M | -16.1M | 11.3M | 34.3M | - |
| Capital Expenditure | 3.75M | 7.91M | 13.3M | 19.2M | 13.3M | 17.5M | 16.0M | 11.1M | 13.9M | 6.30M | 0.00 |
| Free Cash Flow | 15.6M | -9.50M | 3.24M | -24.7M | -7.37M | -17.8M | -10.0M | -27.2M | 573K | 28.0M | - |
| Ratios | |||||||||||
| ROE | 5.4% | 9.4% | 11.4% | 8.0% | 7.1% | 7.7% | -2.9% | 1.1% | 4.8% | 11.6% | 6.4% |
| ROA | 4.0% | 7.1% | 7.9% | 5.4% | 4.9% | 5.3% | -1.9% | 0.7% | 2.7% | 7.0% | 3.7% |
| Net Profit Margin | 9.2% | 22.0% | 22.7% | 15.0% | 17.4% | 13.7% | -4.2% | 1.5% | 3.6% | 6.0% | 4.5% |
| Debt to Equity | - | - | - | 0.08x | 0.09x | 0.17x | 0.21x | 0.34x | 0.29x | 0.17x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chia Tai Enterprises International Limited dividends
Chia Tai Enterprises International Limited has not paid dividends in the last 9 fiscal years.
Who owns Chia Tai Enterprises International Limited
- Insiders 73.26%
- Institutions 0.11%
- Public & others 26.63%
- Shares outstanding 241M
- Free float 64.4M
Chia Tai Enterprises International Limited company profile
- Company name
- Chia Tai Enterprises International Limited
- Ticker
- CAIHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,000
- Fiscal year end
- December
- Address
- Far East Finance Centre, Central, Hong Kong
- Phone
- 852 2520 1601
- Website
- cp-bio.com
About Chia Tai Enterprises International Limited
CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names. The company offers products such as gut & health enhancement, antibioticsanticoc & antiparasitics, bioprotection, detection kits, enzyme, plant extracts, vaccine, and trade. The company also provides solution for poultry, swine, ruminants, and aquaculture. The Investment segment is engaged in the trading of machinery and the manufacture and sale of automotive parts; and caterpillar products, including excavators, power generators, bulldozers and compactors, as well as spare parts; and the manufacture and sale of motorcycle carburetors. The company serves livestock farms, pharmaceutical companies, trading companies, feed mills, automobile manufacturers, and motorcycle manufacturers. CPBIO Holding Company Limited was formerly known as Chia Tai Enterprises International Limited and changed its name to CPBIO Holding Company Limited in July 2026. CPBIO Holding Company Limited was incorporated in 1987 and is based in Central, Hong Kong.
Chia Tai Enterprises International Limited management
5- Mr. Chawalit Na MuangtounCEO & Executive Director · born 1967
- Mr. Thirayut PhityaisarakulExecutive Director · born 1942
- Mr. Nopadol ChiaravanontExecutive Director · born 1961
- Mr. Soopakij ChearavanontExecutive Chairman · born 1964
- Mr. Wing Yuen LauCompany Secretary · born 1965